118 related articles for article (PubMed ID: 18471157)
61. Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real-life combo study.
Candoni A; Caira M; Cesaro S; Busca A; Giacchino M; Fanci R; Delia M; Nosari A; Bonini A; Cattaneo C; Melillo L; Caramatti C; Milone G; Scime' R; Picardi M; Fanin R; Pagano L;
Mycoses; 2014 Jun; 57(6):342-50. PubMed ID: 24373120
[TBL] [Abstract][Full Text] [Related]
62. The echinocandins.
Cappelletty D; Eiselstein-McKitrick K
Pharmacotherapy; 2007 Mar; 27(3):369-88. PubMed ID: 17316149
[TBL] [Abstract][Full Text] [Related]
63. Micafungin versus amphotericin B lipid complex for the prevention of invasive fungal infections in high-risk liver transplant recipients.
Sun HY; Cacciarelli TV; Singh N
Transplantation; 2013 Sep; 96(6):573-8. PubMed ID: 23842191
[TBL] [Abstract][Full Text] [Related]
64. Toxicities of tacrolimus and cyclosporin A after allogeneic blood stem cell transplantation.
Woo M; Przepiorka D; Ippoliti C; Warkentin D; Khouri I; Fritsche H; Körbling M
Bone Marrow Transplant; 1997 Dec; 20(12):1095-8. PubMed ID: 9466284
[TBL] [Abstract][Full Text] [Related]
65. Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies.
Candoni A; Mestroni R; Damiani D; Tiribelli M; Michelutti A; Silvestri F; Castelli M; Viale P; Fanin R
Eur J Haematol; 2005 Sep; 75(3):227-33. PubMed ID: 16104879
[TBL] [Abstract][Full Text] [Related]
66. Micafungin use in children.
Emiroglu M
Expert Rev Anti Infect Ther; 2011 Sep; 9(9):821-34. PubMed ID: 21905789
[TBL] [Abstract][Full Text] [Related]
67. Different doses of micafungin for prophylaxis of invasive fungal diseases in hemato-oncological high-risk patients: a web-based non-interventional trial in four large university hospitals in Germany.
Heimann SM; Vehreschild MJ; Meintker L; Heinz W; Schroeder T; von Bergwelt-Baildon M; Cornely OA; Vehreschild JJ
Transpl Infect Dis; 2014 Dec; 16(6):968-74. PubMed ID: 25371351
[TBL] [Abstract][Full Text] [Related]
68. Invasive Saccharomyces cerevisiae in a liver transplant patient: case report and review of infection in transplant recipients.
Popiel KY; Wong P; Lee MJ; Langelier M; Sheppard DC; Vinh DC
Transpl Infect Dis; 2015 Jun; 17(3):435-41. PubMed ID: 25827213
[TBL] [Abstract][Full Text] [Related]
69. Caspofungin.
Deresinski SC; Stevens DA
Clin Infect Dis; 2003 Jun; 36(11):1445-57. PubMed ID: 12766841
[TBL] [Abstract][Full Text] [Related]
70. Anidulafungin treatment in a kidney transplant recipient with hepatic damage.
De Rosa FG; Manzione NA; Ranghino A; Messina M; Ottobrelli A; Raviolo S; Di Perri G; Segoloni GP
Mycoses; 2011 Dec; 54 Suppl 4():12-5. PubMed ID: 22126524
[TBL] [Abstract][Full Text] [Related]
71. Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients.
Würthwein G; Young C; Lanvers-Kaminsky C; Hempel G; Trame MN; Schwerdtfeger R; Ostermann H; Heinz WJ; Cornely OA; Kolve H; Boos J; Silling G; Groll AH
Antimicrob Agents Chemother; 2012 Jan; 56(1):536-43. PubMed ID: 22083471
[TBL] [Abstract][Full Text] [Related]
72. Tacrolimus therapy causes hepatotoxicity in patients with a history of liver disease.
Ko MS; Choi YH; Jung SH; Lee JS; Kim HS; Lee CH; Kim SG
Int J Clin Pharmacol Ther; 2015 May; 53(5):363-71. PubMed ID: 25740263
[TBL] [Abstract][Full Text] [Related]
73. Successful treatment of cutaneous alternariosis with caspofungin in a renal transplant recipient.
Seyfarth F; Goetze S; Gräser Y; Kaatz M; Ott U; Rüster C; Edel B; Elsner P; Hipler UC
Mycoses; 2012 Sep; 55(5):457-62. PubMed ID: 22329778
[No Abstract] [Full Text] [Related]
74. Factors influencing caspofungin plasma concentrations in kidney transplant patients with high incidence of invasive fungal infections.
Yang Q; Zhang T; Zhao D; Zhang Y; Dong Y; Sun D; Du Q; Zheng J; Lu H; Dong Y
J Clin Pharm Ther; 2020 Feb; 45(1):72-80. PubMed ID: 31468555
[TBL] [Abstract][Full Text] [Related]
75. Hepatic safety of caspofungin during treatment of invasive fungal diseases in elderly patients.
Wang LL; Zhuge X; Xiao GH; Zhang Y
Chin Med J (Engl); 2012 Jun; 125(12):2240. PubMed ID: 22884162
[No Abstract] [Full Text] [Related]
76. Echinocandin-induced eosinophilia: a case report.
Chua NG; Zhou YP; Lingegowda PB; Kwa AL; Lee W
Scand J Infect Dis; 2014 Nov; 46(11):809-12. PubMed ID: 25119439
[TBL] [Abstract][Full Text] [Related]
77. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery.
Condie CK; Tyler LS; Barker B; Canann DM
Am J Health Syst Pharm; 2008 Mar; 65(5):454-7. PubMed ID: 18281738
[TBL] [Abstract][Full Text] [Related]
78. Pharmacokinetics of caspofungin increased dosage in a patient on rifampin-containing anti-tubercular treatment.
Calcagno A; Baietto L; Pagani N; Bertucci R; Rostagno R; D'Avolio A; Di Perri G; De Rosa FG
Scand J Infect Dis; 2013 Nov; 45(11):882-4. PubMed ID: 23796067
[TBL] [Abstract][Full Text] [Related]
79. Optimal oral cyclosporin dosing with concomitant posaconazole post allogeneic stem cell transplantation.
Robinson DH; Hughes CFM; Grigg A
Leuk Lymphoma; 2020 Oct; 61(10):2448-2452. PubMed ID: 32476517
[TBL] [Abstract][Full Text] [Related]
80. [Fungal infections in heart transplantation].
Mitsutake K
Nihon Ishinkin Gakkai Zasshi; 2001; 42(4):195-9. PubMed ID: 11704744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
